Kao-Ping Chua1,2,3, Mark G Shrime4,5,6, Rena M Conti2,7. 1. Section of Academic Pediatrics, Departments of Pediatrics, chuak@med.umich.edu. 2. Public Health Sciences and. 3. Department of Pediatrics and Communicable Diseases, Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, Michigan. 4. Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. 5. Department of Otolaryngology, and. 6. Program in Global Surgery and Social Change, Harvard Medical School, Boston, Massachusetts. 7. Pediatric Hematology/Oncology, University of Chicago, Chicago, Illinois.
Abstract
BACKGROUND: In August 2012, the Food and Drug Administration investigated the safety of codeine use by children after tonsillectomy and/or adenoidectomy, culminating in a black box warning in February 2013. The objective of this study was to evaluate the association between the investigation and opioid prescribing to children undergoing these surgeries. METHODS: We identified 362 992 privately insured children in the 2010-2015 Truven MarketScan Commercial Claims and Encounters database who underwent tonsillectomy and/or adenoidectomy. Using an interrupted time series design, we estimated level and slope changes in the proportion of children with ≥1 prescription fills for codeine and ≥1 fills for an alternative opioid, such as hydrocodone, within 7 days of surgery. RESULTS: The investigation was associated with a significant -13.3 (95% confidence interval: -14.5 to -12.1) percentage point level change in the proportion of children with ≥1 prescription fills for codeine after tonsillectomy and/or adenoidectomy. Despite this drop, 5.1% of children had ≥1 prescription fills for codeine in December 2015. The investigation was not associated with significant level changes in alternative opioid prescribing, although the proportion of children receiving alternative opioids increased during the study period because of other factors. CONCLUSIONS: The Food and Drug Administration investigation substantially decreased codeine prescribing to children after tonsillectomy and/or adenoidectomy. However, 1 in 20 children undergoing these surgeries were still prescribed codeine in December 2015 despite its well-documented safety and efficacy issues.
BACKGROUND: In August 2012, the Food and Drug Administration investigated the safety of codeine use by children after tonsillectomy and/or adenoidectomy, culminating in a black box warning in February 2013. The objective of this study was to evaluate the association between the investigation and opioid prescribing to children undergoing these surgeries. METHODS: We identified 362 992 privately insured children in the 2010-2015 Truven MarketScan Commercial Claims and Encounters database who underwent tonsillectomy and/or adenoidectomy. Using an interrupted time series design, we estimated level and slope changes in the proportion of children with ≥1 prescription fills for codeine and ≥1 fills for an alternative opioid, such as hydrocodone, within 7 days of surgery. RESULTS: The investigation was associated with a significant -13.3 (95% confidence interval: -14.5 to -12.1) percentage point level change in the proportion of children with ≥1 prescription fills for codeine after tonsillectomy and/or adenoidectomy. Despite this drop, 5.1% of children had ≥1 prescription fills for codeine in December 2015. The investigation was not associated with significant level changes in alternative opioid prescribing, although the proportion of children receiving alternative opioids increased during the study period because of other factors. CONCLUSIONS: The Food and Drug Administration investigation substantially decreased codeine prescribing to children after tonsillectomy and/or adenoidectomy. However, 1 in 20 children undergoing these surgeries were still prescribed codeine in December 2015 despite its well-documented safety and efficacy issues.
Authors: James A Feinstein; Jonathan Rodean; Matt Hall; Stephanie K Doupnik; James C Gay; Jessica L Markham; Jessica L Bettenhausen; Julia Simmons; Brigid Garrity; Jay G Berry Journal: Pediatrics Date: 2019-06 Impact factor: 7.124
Authors: Cecilia P Chung; Stephen Todd Callahan; William O Cooper; William D Dupont; Katherine T Murray; Andrew D Franklin; Kathi Hall; Judith A Dudley; Charles Michael Stein; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2019-08-16 Impact factor: 2.890
Authors: Karin Hedenmalm; Kevin Blake; Katherine Donegan; Miguel-Angel Macia; Miguel Gil; Julie Williams; Dolores Montero; Gianmario Candore; Daniel Morales; Xavier Kurz; Peter Arlett Journal: Pharmacoepidemiol Drug Saf Date: 2019-06-20 Impact factor: 2.890
Authors: Amy Lawrence; Jennifer N Cooper; Katherine J Deans; Peter C Minneci; Sharon K Wrona; Deena J Chisolm Journal: Glob Pediatr Health Date: 2021-01-15
Authors: Lorraine I Kelley-Quon; Matthew G Kirkpatrick; Robert L Ricca; Robert Baird; Calista M Harbaugh; Ashley Brady; Paula Garrett; Hale Wills; Jonathan Argo; Karen A Diefenbach; Marion C W Henry; Juan E Sola; Elaa M Mahdi; Adam B Goldin; Shawn D St Peter; Cynthia D Downard; Kenneth S Azarow; Tracy Shields; Eugene Kim Journal: JAMA Surg Date: 2021-01-01 Impact factor: 14.766